FI932872A0 - 14b-H-, 14- och 15-en-11b-aryl-4-estrener - Google Patents

14b-H-, 14- och 15-en-11b-aryl-4-estrener

Info

Publication number
FI932872A0
FI932872A0 FI932872A FI932872A FI932872A0 FI 932872 A0 FI932872 A0 FI 932872A0 FI 932872 A FI932872 A FI 932872A FI 932872 A FI932872 A FI 932872A FI 932872 A0 FI932872 A0 FI 932872A0
Authority
FI
Finland
Prior art keywords
hydrogen atom
pct
bond
configuration
together represent
Prior art date
Application number
FI932872A
Other languages
English (en)
Other versions
FI932872A (fi
Inventor
Wolfgang Schwede
Eckhard Ottow
Guenter Neef
Arwed Cleve
Krzysztof Chwalisz
Horst Michna
Ulrike Fuhrmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI932872A publication Critical patent/FI932872A/fi
Publication of FI932872A0 publication Critical patent/FI932872A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092—Alkenyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Internal Circuitry In Semiconductor Integrated Circuit Devices (AREA)
  • Luminescent Compositions (AREA)
  • Amplifiers (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electron Beam Exposure (AREA)
FI932872A 1990-12-22 1993-06-21 14b-H-, 14- och 15-en-11b-aryl-4-estrener FI932872A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4042004A DE4042004A1 (de) 1990-12-22 1990-12-22 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
PCT/EP1991/002494 WO1992011278A1 (de) 1990-12-22 1991-12-21 14β-H-, 14- UND 15-EN-11β-ARYL-4-ESTRENE

Publications (2)

Publication Number Publication Date
FI932872A FI932872A (fi) 1993-06-21
FI932872A0 true FI932872A0 (fi) 1993-06-21

Family

ID=6421576

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932872A FI932872A0 (fi) 1990-12-22 1993-06-21 14b-H-, 14- och 15-en-11b-aryl-4-estrener

Country Status (14)

Country Link
US (1) US5426102A (fi)
EP (1) EP0567469B1 (fi)
JP (1) JP3048636B2 (fi)
CN (1) CN1066271A (fi)
AT (1) ATE157372T1 (fi)
AU (1) AU659118B2 (fi)
CA (1) CA2099016A1 (fi)
DE (2) DE4042004A1 (fi)
FI (1) FI932872A0 (fi)
HU (1) HUT65320A (fi)
IE (1) IE914530A1 (fi)
PT (1) PT99910B (fi)
WO (1) WO1992011278A1 (fi)
ZA (1) ZA9110145B (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
CA2668824A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secre Tary Of The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US6090798A (en) * 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
EP1613640A4 (en) * 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
ES2762243T3 (es) 2010-05-26 2020-05-22 Corcept Therapeutics Inc Tratamiento de distrofia muscular
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
JP2785023B2 (ja) * 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide

Also Published As

Publication number Publication date
CA2099016A1 (en) 1992-06-23
JP3048636B2 (ja) 2000-06-05
HUT65320A (en) 1994-05-02
ATE157372T1 (de) 1997-09-15
PT99910B (pt) 1999-06-30
DE59108837D1 (de) 1997-10-02
CN1066271A (zh) 1992-11-18
FI932872A (fi) 1993-06-21
ZA9110145B (en) 1992-11-25
DE4042004A1 (de) 1992-06-25
HU9301813D0 (en) 1993-09-28
AU9111091A (en) 1992-07-22
PT99910A (pt) 1992-12-31
JPH06505708A (ja) 1994-06-30
US5426102A (en) 1995-06-20
WO1992011278A1 (de) 1992-07-09
AU659118B2 (en) 1995-05-11
EP0567469A1 (de) 1993-11-03
IE914530A1 (en) 1993-06-30
EP0567469B1 (de) 1997-08-27

Similar Documents

Publication Publication Date Title
DE59108837D1 (de) 14beta-H-, 14- UND 15-EN-11beta-ARYL-4-ESTRENE
IL105078A (en) Pharmaceutical compositions containing 17-(3-pyridyl)- substituted steroids and some new compounds of this type
ES8401498A1 (es) Procedimiento de preparacion de nuevos derivados esteroides sustituidos en 11b.
ZA929859B (en) 19-nor steroids having a thiocarbon chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them
FI932873A0 (fi) D-homo-(16-en)-11b-aryl-4-estrener, foerfarande foer deras framstaellningoch deras anvaendning som laekemedel
FI932874A0 (fi) 6,7-modifierade 11b-aryl-4-estrener
HUP0401829A2 (hu) Szubsztituált 1H-kinoxalin-2-on-vegyületek és szubsztituált 4-aril- vagy 4-heteroaril-ciklohexán-vegyületek, eljárás az előállításukra és az 1H-kinoxalin-2-on vegyületeket tartalmazó gyógyszerkészítmények
HUP0300887A2 (hu) Szteroid szerkezeteket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE50110892D1 (de) 17alpha-fluoralkylsteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
CA2395481A1 (en) Hormone receptor modulation
TR200001405T2 (tr) 11ß pozisyonunda ikameli/katkılı yeni 19-nor steroidler hazırlama metodu-ara maddeleri.
ES8403109A1 (es) Un procedimiento para la preparacion de 4-(3-trifluormetilfenil)-1,2,3,6-tetrahidropiridinas.
NO932276L (no) D-homo-(16-en)-11beta-aryl-4-oestrener, fremgangsmaate for deres fremstilling, saa vel som deres anvendelse som legemiddel
MX9707610A (es) Derivados de fenoxietilamina que tienen una afinidad elevada hacia el receptor 5-ht1a, su procedimiento de preparacion, su aplicacion como medicamento y las composiciones farmaceuticas que los contienen.
GB928493A (en) Steroid compounds
JP2001316364A (ja) 新規テトラヒドロベンズインドロン誘導体及びそれらの製造法
HUP0302020A2 (hu) 2-Szubsztituált pregna-1,3,5,(10)-trién- és kola-1,3,5(10)-trién-származékok, eljárás elżállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
FD Application lapsed